Skip to Main Content

Try STAT+ TODAY

HIV/AIDS

Most Read

In the Lab Angus Chen

Early research suggests cancer drug could help flush HIV from its hiding spots

First Opinion Kathryn Macapagal

This HIV prevention medicine is for everyone. Why do so few people take it?

First Opinion Jason Silverstein

Eliminating the FDA’s blood donation ban on men who have sex with men would help ease the U.S. shortage

In the Lab Megan Molteni

Scientists report finding a second person to be ‘naturally’ cured of HIV, raising hopes for future treatments

Health Matthew Herper

Johnson & Johnson’s HIV vaccine fails first efficacy trial

First Opinion Jonathan Cohen

A vaccine for my shame

In the Lab Natalya Ortolano

Experimental HIV drug seems effective at a twice-a-year dose, study finds

Health Usha Lee McFarling

Why the porn industry has a lot to teach us about safety in the Covid-19 era

All Coverage

First Opinion Mandeep Dhaliwal

Decriminalizing HIV: Scientifically proven and morally correct

First Opinion Linda-Gail Bekker and Mitchell Warren

Stop squandering opportunities to end AIDS: be responsive to the needs of HIV prevention users

advertisement

Health Jason Mast

How the hard lessons of the AIDS crisis are shaping the response to the monkeypox outbreak

Pharmalot Ed Silverman

STAT Plus: ViiV causes an outcry by declining to pursue voluntary licensing for its HIV prevention shot

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Former Rochester CEO is convicted over opioid crisis; Covid-19 therapies appear cost-effective

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Biden administration used hospital funds to buy Covid vaccines and drugs; a cancer drug may help combat HIV

Pharmalot Ed Silverman

STAT Plus: By endorsing a first injectable for HIV prevention, FDA creates alternative to pills and a battle among drug makers

First Opinion Rachel Vreeman

Losing Faith: Reflecting on 40 years of the HIV pandemic

First Opinion David Malebranche

Stigma, not science, is the biggest barrier to ending the HIV epidemic

Health Maddie Bender

Despite interventions, Black and Hispanic men are contracting HIV at the same rates as 10 years ago

Health Nicholas St. Fleur

Virtual Event: The next battles in the war against HIV

First Opinion Kenneth H. Mayer

40 years of AIDS taught us epidemiologic humility. We need to apply that lesson in fighting Covid-19

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Merck says early data shows pill is effective against Covid-19; WHO’s COVAX program ships first doses

Pharmalot Ed Silverman

STAT Plus: New Mexico attorney general accuses Gilead of blocking competition to its HIV medicines

Pharmalot Ed Silverman

FDA approves first monthly injectable to treat HIV infection

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Pfizer Covid-19 vaccine shows 95% effectiveness; FDA vows to disclose scientific data for EUAs

Health Associated Press

AIDS report: Kids are lagging and Covid-19 is harming care

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Covid-19 trials are marked by disorganization; FDA approves a new type of HIV treatment

Health Usha Lee McFarling

‘Flying blind’: Doctors race to understand what Covid-19 means for people with HIV

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Stressed Americans cause a shortage of an antidepressant; Dems attack GOP candidates over malaria drug

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: U.K. will get first access to an AstraZeneca Covid-19 vaccine; VA will continue using old malaria drug

Pharmalot Ed Silverman

STAT Plus: Gilead sues U.S., claiming it ‘secretly’ obtained patents on HIV research that led to Truvada

Pharmalot Ed Silverman

STAT Plus: AbbVie waives all worldwide restrictions on making generic copies of its Kaletra HIV pill

Pharmalot Ed Silverman

STAT Plus: A recently approved Gilead HIV prevention pill is not cost-effective and price should be cut in half, study says

First Opinion Douglas Krakower, Kenneth Katz and Julia L. Marcus

Will the newest pill for HIV prevention fuel progress — or profits?